Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
Sponsor: Ryazan State Medical University
Summary
The study is aimed at assessing the role of the activity of markers of endothelial dysfunction (cytotoxic malonic aldehyde (MDA), angiotensin II, endothelial nitric oxide synthase (NO), endothelin-1, prostacyclin) in the systemic circulation in patients with lower extremity atherosclerotic arterial occlusive disease undergoing open reconstructive interventions.
Official title: Evaluation of the Efficacy and Safety of the Drug Based on Vascular Regulatory Polypeptides for the Treatment of Patients With Lower Extremity Atherosclerotic Arterial Occlusive Disease.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2023-04-01
Completion Date
2026-09-01
Last Updated
2023-07-06
Healthy Volunteers
No
Conditions
Interventions
Polypeptides
The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
Femoral-popliteal bypass grafting with a synthetic graft above the knee
The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
Routine conservative treatment
The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
Locations (1)
RyazanSMU
Ryazan, Russia